Navigation Links
Cambrex Reports Fourth Quarter and Full-Year 2007 Results
Date:2/14/2008

EAST RUTHERFORD, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Cambrex Corporation (NYSE: CBM) reports fourth quarter and full-year 2007 results for the period ended December 31, 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )

Summary

-- Fourth quarter 2007 sales increased 5.7% (-0.2% excluding foreign

currency) compared to fourth quarter 2006. Full year sales were up

6.7% (2.0% excluding foreign currency) compared to 2006.

-- Gross Margin for the quarter increased to 34.9% of sales compared to

33.5% last year. Full year Gross Margin increased to 36.1% compared

to 35.4% in 2006.

-- Operating Profit before corporate, strategic alternatives and

restructuring expenses was $13.3 million or 19.1% of sales in the

fourth quarter of 2007 versus $12.9 million or 19.6% last year. For

the full year, Operating Profit before corporate, strategic

alternatives and restructuring expenses was $51.1 million or 20.2% of

sales, versus $49.2 million or 20.8% for 2006.

-- Debt, net of cash, was $63.3 million at the end of 2007.

-- Sales growth for 2008 is expected to be between 5% and 10% and

Adjusted EBITDA (EBITDA before restructuring and strategic

alternatives costs) is expected to be between $53 and $57 million.

Discontinued Operations and Basis of Reporting

As previously reported, Cambrex sold its Bioproducts and Biopharma businesses (the "Bio Businesses") to Lonza for $463.9 million (after working capital adjustments) in February 2007 and sites in Cork, Ireland and Landen, Bel % of % of

Amount Sales Amount Sales

Gross Sales $252,574 100.0% $236,659 100.0%

Commissions and Allowances 1,368 0.5% 1,026 0.4%

Net Sales 251,206 99.5% 235,633 99.6%

Other Revenues 1,299 0.5% (560) -0.3%

Net Revenue 252,505 100.0% 235,073 99.3%

Cost of Sales 161,273 63.9% 151,215 63.9%

Gross Profit 91,232 36.1% 83,858 35.4%

Operating Expenses

Sales, General and Administrative

Expenses 48,858 19.4% 58,279 24.6%

Research and Development Expenses 12,157 4.8% 10,813 4.6%

Restructuring Expenses 6,073 2.4% - 0.0%

Strategic Alternative Costs 31,127 12.3% 2,958 1.2%

Total Operating Expenses 98,215 38.9% 72,050 30.4%

Operating (Loss)/Profit (6,983) -2.8% 11,808 5.0%

Other (Income)/Expenses:

Interest (Income)/Expense, net (485) -0.2% 5,478 2.3%

Other Expense/(Income), net 725 0.3% (17) 0.0%

(Loss)/Income Before Income Taxes (7,223) -2.9% 6,347 2.7%

Provision for Income Taxes 5,773 2.2% 14,513 6.2%

Loss from Continuing Operations $(12,996) -5.1% $(8,166) -3.5%

Income/(Loss) from Discontinued

Operations, Net of Tax 222,759 88.2% (21,706) -9.1%

Income/(Loss) Before Cumulative Effect

of a Change in

Accounting Principle 209,763 83.1% (29,872) -12.6%

Cumulative Effect of a Change in

Accounting Principle - 0.0% (228) -0.1%

Net Income/(Loss) $209,763 83.1% $(30,100) -12.7%

Basic (Loss)/Earnings per Share

Loss from Continuing Operations $(0.45) $(0.30)

Income/(Loss) from Discontinued

Operations, Net of Tax $7.76 $(0.81)

Cumulative Effect of a Change in

Accounting Principle $- $(0.01)

Net Income/(Loss) $7.31 $(1.12)

Diluted (Loss)/Earnings per Share

Loss from Continuing Operations $(0.45) $(0.30)

Income/(Loss) from Discontinued

Operations, Net of Tax $7.76 $(0.81)

Cumulative Effect of a Change in

Accounting Principle $- $(0.01)

Net Income/(Loss) $7.31 $(1.12)

Weighted Average Shares Outstanding

Basic 28,683 26,816

Diluted 28,683 26,816

CAMBREX CORPORATION

Reconciliation of Gross Sales, Gross Profit & Operating Profit

For the Quarters and Years Ended December 31, 2007 and 2006

(in thousands)

Fourth Quarter 2007

Gross Gross Operating

Sales Profit GP% Profit/(Loss) OP%

Pre-Corporate Results

Before Strat. Alt.

& Restructuring

Expenses $69,754 $24,378 34.9% $13,293 19.1%

Corporate Results - - (4,735)

Strat. Alt. &

Restructuring Expenses - - (4,606)

As Reported $69,754 $24,378 34.9% $3,952 5.7%

Fourth Quarter 2006

Gross Gross Operating

Sales Profit GP% Profit/(Loss) OP%

Pre-Corporate Results $66,009 $22,081 33.5% $12,911 19.6%

Corporate Results - - (9,658)

Strategic Alternative

Costs - - (726)

As Reported $66,009 $22,081 33.5% $2,527 3.8%

Twelve Months 2007

Gross Gross Operating

Sales Profit GP% Profit/(Loss) OP%

Pre-Corporate Results

Before Strat. Alt.

& Restructuring

Expenses $252,574 $91,232 36.1% $51,076 20.2%

Corporate Results - - (20,859)

Strat. Alt. &

Restructuring Expenses - - (37,200)

As Report $252,574 $91,232 36.1% $(6,983) -2.8%

Twelve Months 2007

Pre-Corporate Operating Profit Before

Strat. Alt. & Restructuring Expenses $51,076

Corporate Results (20,859)

Depreciation and Amortization 19,878

Adjusted EBITDA $50,095

Twelve Months 2006

Gross Gross Operating

Sales Profit GP% Profit/(Loss) OP%

Pre-Corporate Results $236,659 $83,858 35.4% $49,213 20.8%

Corporate Results - - (34,447)

Strategic Alternative

Costs - - (2,958)

As Reported $236,659 $83,858 35.4% $11,808 5.0%

CAMBREX CORPORATION

Consolidated Balance Sheet

As of December 31, 2007 and 2006

(in thousands)

December 31, December 31,

Assets 2007 2006

Cash and Cash Equivalents $38,488 $33,746

Trade Receivables, net 45,003 38,552

Inventories, net 61,440 53,893

Assets of Discontinued Operations - 79,527

Prepaid Expenses and Other Current

Assets 22,294 19,032

Total Current Assets 167,225 224,750

Property, Plant and Equipment, Net 165,657 141,863

Goodwill 35,552 32,573

Assets of Discontinued Operations - 202,292

Other Non-Current Assets 10,383 4,898

Total Assets $378,817 $606,376

Liabilities and Stockholders' Equity

Accounts Payable $26,185 $28,592

Accrued Expenses and Other Current

Liabilities 71,274 45,101

Liabilities of Discontinued

Operations - 33,441

Total Current Liabilities 97,459 107,134

Long-term Debt 101,600 158,600

Deferred Tax Liabilities 19,918 14,209

Liabilities of Discontinued

Operations - 24,267

Accrued Pension and Postretirement

Benefits 32,104 39,911

Other Non-Current Liabilities 25,244 15,609

Total Liabilities $276,325 $359,730

Stockholders' Equity $102,492 $246,646

Total Liabilities and Stockholders'

Equity $378,817 $606,376

gium to ICIG during the fourth quarter of 2006. Discontinued Operations in the 2007 financial statements include the results of operations of the Bio Businesses through the date of sale as well as the corresponding gain on sale. Discontinued Operations for 2007 also include charges related to the previously announced settlement of the Rutherford litigation and environmental expenses related to a site of a divested business. Discontinued Operations in the 2006 financial statements include the results of operations of the Bio Businesses and the Cork and Landen sites, as well as the loss on the sale of the Cork and Landen sites.

The Company has provided a reconciliation from adjusted amounts to GAAP amounts at the end of this press release. Management believes that the adjusted amounts provide a more meaningful representation of the Company's operating results for the periods presented due to the magnitude and nature of certain expenses recorded.

Fourth Quarter 2007 Operating Results - Continuing Operations

Fourth quarter 2007 sales of $69.8 million were 5.7% higher than sales in the fourth quarter 2006, and were virtually flat excluding the effect of foreign currency. Comparing the current quarter to the same quarter last year, excluding the currency impact, Cambrex experienced lower custom development revenues primarily as a result of customers ramping up inventory during the fourth quarter of 2006 for expected product launches in 2007 and lower pricing on custom manufacturing and crop protection products, offset by higher demand for a neurological active pharmaceutical ingredient ("API"), controlled substances and products based on our proprietary polymeric drug delivery technology.

Fourth quarter 2007 Gross Margin increased to 34.9% of sales from 33.5% during the fourth quarter 2006 resulting primarily from favorable product mix partially offset by lower pricing on certain APIs. Foreign currency favorably impacted gross margin, as a percentage of sales, by 1.2%.

Operating Profit was $4.0 million in the fourth quarter of 2007 compared to $2.5 million for the fourth quarter of 2006. Operating Profit before corporate, strategic alternatives and restructuring expenses was $13.3 million, or 19.1% of sales, compared to $12.9 million, or 19.6% of sales, in the fourth quarter 2006 due to favorable foreign exchange partially offset by higher Operating Expenses.

James A. Mack, Chairman, President, and Chief Executive Officer of Cambrex Corporation, said "2007 was a very satisfying year for Cambrex. We completed our strategic alternatives initiative during the first half of the year culminating in a $400 million dividend, and further enhanced the value of the business during the back half of the year by eliminating most of our significant legal contingencies and dramatically reducing our corporate overhead to a $17 million run rate heading into 2008. We continue to grow sales of products based on our polymeric drug delivery technologies and are very excited about the positive effect it has had and should continue to have on our profitability mix. We will continue to add dedicated resources to expand the application of our existing proprietary technologies and enhance our portfolio of intellectual property. A few weeks ago, we completed a small acquisition in Estonia that will allow us to grow our early-stage custom development pipeline and free up internal resources to focus on expanding our proprietary technologies. 2007 was also a good year for our custom development pipeline. In addition to growing the number of projects in the pipeline, we also completed 85 projects, a new record for Cambrex. Lastly, our new state-of-the-art finishing facility in Italy is in the start-up phase and the first APIs are going through the validation process."

Fourth Quarter 2007 Operating, Interest and Tax Expenses - Continuing Operations

Sales, General and Administrative ("SG&A") Expenses in the fourth quarter 2007 were $12.3 million compared to $16.1 million in the same period last year. The reduction is primarily due to significantly lower expenses at the corporate headquarters due to restructuring activities completed throughout 2007 and was partially offset by higher personnel-related expenses at our operating sites. Within SG&A, corporate expenses in the fourth quarter of 2007 were decreased to $4.7 million compared to $9.7 million in the same period last year due to the restructuring of the corporate headquarters.

Research and Development Expense for the fourth quarter 2007 was $3.5 million compared to $2.8 million in the fourth quarter 2006. The increase is primarily due to investment in the growth and development of proprietary technology platforms, and higher costs at the recently closed New Jersey R&D facility due to lower utilization of scientists on revenue-generating projects.

Strategic Alternative and Restructuring Costs totaling $4.6 million in the fourth quarter 2007 include $2.1 million of costs related to the previously announced consolidation of operations at our New Jersey R&D facility into our Charles City facility resulting in the shutdown of the New Jersey facility, $1.0 million of costs related to the exit of a feed additive business at our Charles City facility, and $1.5 million of expense related to change-in- control liabilities and a project to streamline our legal structure to improve cash flow and reduce the Company's consolidated effective tax rate.

Net Interest Expense in the fourth quarter of 2007 increased to $0.9 million from $0.2 million of income in the fourth quarter of 2006. The increase is primarily due to the adjustment in 2006 results for GAAP-required allocations of interest expense to Discontinued Operations.

Income taxes for the fourth quarter and full year 2007 include $1.1 million and $7.9 million, respectively, of benefit related to the recognition of certain tax attributes as a result of the sale of the Bio Businesses. Excluding these benefits, the fourth quarter and full year 2007 Provision for Income Taxes would have been $2.7 million and $13.7 million respectively. The Company's effective tax rates have been, and are expected to, remain highly sensitive to the geographic mix of income due to the Company's inability to recognize tax benefits for GAAP purposes in certain jurisdictions where there has been a recent history of losses, primarily the U.S.

Fourth Quarter 2007 Capital Expenditures and Depreciation

Capital expenditures and depreciation for the fourth quarter 2007 were $11.6 million and $5.3 million compared to $13.3 million and $4.4 million in the fourth quarter 2006, respectively. The decrease in capital spending is largely due to reduced spending on a new API finishing facility at our Milan, Italy site that will be validated throughout 2008, partially offset by early spending related to a mid-scale manufacturing facility in Sweden that is expected to be validated in early 2009. Capital expenditures for the full year 2007 were $33.6 million and depreciation was $19.8 million.

Guidance - Continuing Operations

Sales growth during 2008 is expected to be between 5% and 10% and Adjusted EBITDA is expected to be $53 to $57 million, compared to $50.1 million for the full year 2007. Restructuring and strategic alternatives costs are expected to be between $1.0 million and $1.5 million primarily related to finalizing the closure of our New Jersey R&D facility, completing the project to improve our legal entity structure and exiting a feed additive business.

For 2008, capital expenditures are expected to be approximately $32 to 34 million and depreciation is expected to be $21 to 23 million.

Full year and quarterly effective tax rates will continue to be highly sensitive due to the geographic mix of income or losses. Cambrex may not be able to recognize tax benefits in certain jurisdictions.

The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the 2007 Form 10- K is filed with the SEC.

Conference Call and Webcast

The Conference Call to discuss fourth quarter and full-year 2007 earnings will begin at 8:30 a.m. Eastern Time on Friday, February 15, 2008 and last approximately 45 minutes. Those wishing to participate should call 1-888-634- 4003 for domestic and +1-706-634-6653 for international. Please use the pass code 33830541 and call approximately 10 minutes prior to start time. A webcast is available from the Investor Relations section on the Cambrex website located at http://www.cambrex.com and can be accessed for approximately a month following the call. A telephone replay of the conference call will be available through Friday, February 22, 2008 by calling 1-800-642-1687 for domestic and +1-706-645-9291 for international. Please use the pass code 33830541 to access the replay.

Forward Looking Statements

This news release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that words such as "expects", "anticipates", "intends", "estimates", "believes" or similar expressions are used in connection with any discussion of future financial or operating performance. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in the Company's periodic reports filed with the U.S. Securities and Exchange Commission. Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation or regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and the accuracy of the Company's current estimate with respect to its earnings and profits for tax purposes in 2007. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time and it is not possible for the Company to predict which new factors will arise. In addition, we cannot assess the impact of each factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors and security holders are cautioned to review the Cambrex 2006 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other subsequent filings with the U.S. Securities and Exchange Commission , including Current Reports on Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule APIs, advanced intermediates and other products for branded and generic pharmaceuticals. The Company currently employs approximately 850 people worldwide. For more information, please visit http://www.cambrex.com.

CAMBREX CORPORATION

Statement of Profit and Loss

For the Quarters Ended December 31, 2007 and 2006

(in thousands)

2007 2006

% of % of

Amount Sales Amount Sales

Gross Sales $69,754 100.0% $66,009 100.0%

Commissions and Allowances 367 0.5% 129 0.2%

Net Sales 69,387 99.5% 65,880 99.8%

Other Revenues 435 0.6% 274 0.4%

Net Revenues 69,822 100.1% 66,154 100.2%

Cost of Goods Sold 45,444 65.2% 44,073 66.7%

Gross Profit 24,378 34.9% 22,081 33.5%

Operating Expenses

Sales, General and Administrative

Expenses 12,286 17.5% 16,077 24.4%

Research and Development Expenses 3,534 5.1% 2,751 4.2%

Restructuring Expenses 2,039 2.9% - 0.0%

Strategic Alternative Costs 2,567 3.7% 726 1.1%

Total Operating Expenses 20,426 29.2% 19,554 29.7%

Operating Profit 3,952 5.7% 2,527 3.8%

Other Expenses/(Income):

Interest Expense/(Income), net 856 1.3% (163) -0.3%

Other Income, net (205) -0.3% (147) -0.2%

Income Before Income Taxes 3,301 4.7% 2,837 4.3%

Provision for Income Taxes 1,573 2.2% 4,046 6.1%

Income/(Loss) from Continuing

Operations $1,728 2.5% $(1,209) -1.8%

Loss from Discontinued Operations,

Net of Tax (948) -1.4% (24,158) -36.6%

Net Income/(Loss) $780 1.1% $(25,367) -38.4%

Basic (Loss)/Earnings per Share

Income/(Loss) from Continuing

Operations $0.06 $(0.04)

Loss from Discontinued Operations,

Net of Tax $(0.03) $(0.90)

Net Income/(Loss) $0.03 $(0.94)

Diluted (Loss)/Earnings per Share

Income/(Loss) from Continuing

Operations $0.06 $(0.04)

Loss from Discontinued Operations,

Net of Tax $(0.03) $(0.90)

Net Income/(Loss) $0.03 $(0.94)

Weighted Average Shares Outstanding

Basic 29,002 27,108

Diluted 29,040 27,108

CAMBREX CORPORATION

Statement of Profit and Loss

For the Years Ended December 31, 2007 and 2006

(in thousands)

2007 2006


'/>"/>

SOURCE Cambrex Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cambrex Signs Agreement To Acquire ProSyntest AS
2. Cambrex To Announce Third Quarter 2007 Financial Results on November 1, 2007
3. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
4. TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year
5. The Quantum Group Reports 4th Quarter and Year End Results for Fiscal Year 2007
6. Kaiser Foundation Health Plan and Hospitals Reports Fourth Quarter and Fiscal Year-End 2007 Financial Results
7. AtriCure Reports Fourth Quarter and Full Year 2007 Record Financial Results
8. Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69
9. AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share
10. Allscripts Reports Fourth Quarter 2007 Results
11. IRC Reports Claimed Medical Expenses for Auto Injury Claimants Far Outpace Inflation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi and ... who do not do their research and undergo cosmetic dermatology treatments from unqualified practitioners ... of a renaissance and every other month a new treatment or device is launched, ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... called the CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial ... healthcare settings. , Over the last 60 years, studies have shown that ...
(Date:12/4/2016)... ... 03, 2016 , ... While James Earl Jones is known for myriad roles ... show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a very ... in large part due to early detection. Like any other disease, treatments have a ...
(Date:12/4/2016)... CA (PRWEB) , ... December 04, 2016 , ... ... without undergoing major cosmetic surgery can now take advantage of a cosmetic procedure ... advanced skin rejuvenation treatment that reduces the appearance of age spots, fine ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in ... Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New ... Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... innovative, personalized cell-based treatment for a high-risk form of the most common ... Hospital of Philadelphia today reported new results using ... The physician-scientists presented findings at the annual meeting of the American ... Continue Reading ... ...
(Date:12/2/2016)... , Dec 2, 2016 Research and Markets ... newsletter to their offering. ... , , R&D Drug ... Publishing,s proprietary R&D Drug Pipeline Database provides 24/7 online access to ... on the market and on investigational drug candidates in research & ...
(Date:12/2/2016)... Columbia , December 2, 2016 - bioLytical lanza el ... nuevas directrices de la OMS     Continue Reading ... ... , , ... enfermedades infecciosas, ha anunciado hoy que está expandiendo el lanzamiento de su INSTI ...
Breaking Medicine Technology: